BACE1 Inhibitors in Phase 3 Trials for Alzheimer’s are Safe in Moderate Doses, According to Study

BACE1 Inhibitors in Phase 3 Trials for Alzheimer’s are Safe in Moderate Doses, According to Study
amyloidDecreasing aggregates of amyloid beta peptide (Aβ) is the most common strategy for treating Alzheimer's disease. One treatment that is undergoing phase 3 clinical trials is beta site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors, which are predicted to decrease the production of Aβ and prevent neurotoxic fibril and plaque formation. A research group in Germany is studying BACE1 inhibitors in mice to further understand how this treatment works. "BACE1 (beta site amyloid precursor protein cleaving enzyme 1) is the rate limiting protease in amyloid β production, hence a promising drug target for the treatment of Alzheimer’s disease," explained Dr. Jochen Herms in the team's article, "Pharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions," published in the current article of Biological Psychiatry. However, like many treatments for Alzheimer's disease, BACE1 inhibitors have the potential for side-effects. "Since several BACE1 inhibitors are currently being evaluated in clinical phase 3 trials for the treatment of Alzheimer's disease, the identification of potential side effects will be of great importance to ensure a positive clinical
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *